Sufentanil: self-administered opioid for post-operative pain

Zalviso (sufentanil) is licensed to treat with acute moderate to severe post-operative pain in adults. The analgesic is administered by a device designed to deliver a single tablet when the patient requires.

Currently, patients experiencing moderate-to-severe acute pain in hospital may use intravenous patient-controlled analgesia with morphine or hydromorphone. | iSTOCK
Currently, patients experiencing moderate-to-severe acute pain in hospital may use intravenous patient-controlled analgesia with morphine or hydromorphone. | iSTOCK

Zalviso sublingual tablets are self-administered by the patient in response to pain, using the hand-held administration device. They are only for use in hospital and must be prescribed by a specialist in opioid therapy. The device provides a minimum lock-out period of 20 minutes between doses.

Zalviso is intended to overcome the limitations of intravenous patient-controlled analgesia, such as medication delivery errors and complications associated with intravenous delivery.

The maximum recommended duration of treatment is 72 hours.

Post-operative pain relief

Further information
View sufentanil drug record 
Summary of Product Characteristics
Manufacturer: Grunenthal

The efficacy of sublingual sufentanil was shown in three phase III trials in acute pain following major abdominal or orthopaedic surgery: two double-blind placebo-controlled trials (sufentanil, n=430; placebo, n=161) and one open-label active-controlled trial (sufentanil, n=177; morphine, n=180).

In the three trials, sublingual sufentanil was superior to placebo for the primary endpoint, time-weighted sum of pain intensity difference (SPID) from baseline over 48 hours (p≤0.001), and the secondary endpoints, time-weighted SPID (p≤0.004), total pain relief (p≤0.004), and patients global assessment (p≤0.007) over 24, 48 and 72 hours.

In the active-controlled study, a significantly higher proportion of patients rated pain control as 'good' or 'excellent' with sufentanil than with morphine (78.5% vs 65.5%, p=0.007).

Patients in all three studies reported clinically meaningful pain relief within the first hour of treatment with sufentanil, and sufentanil was also considered to be easier to use by healthcare professionals.

Respiratory depression

Nausea and vomiting were the most frequently reported adverse reactions to sufentanil. As an opioid, sufentanil can cause dose-related respiratory depression. Patients with respiratory impairment or reduced respiratory reserve are at higher risk and patients with significant existing respiratory depression should not be given sufentanil.

The effects of sufentanil can be blocked immediately by a specific opioid antagonist such as naloxone.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases